Anacardic acid derivatives with significant α-glucosidase inhibitory activity from Syzygium samarangense

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-03-30 DOI:10.1016/j.phytol.2024.03.016

Yikao Hu , Wen Xu , Li Wang , Yuanbiao He , Yong Zhao

引用次数: 0

Abstract

Our continuous effort to search for antidiabetic constituents from the leaves of Syzygium samarangense resulted in the isolation of one new anacardic acid derivative, 2-[(Z)-nonadec-14-enyl]-6-hydroxylbenzoic acid (1) along with four known analogues (2−5). The new structure was elucidated by means of extensive spectroscopic data including 1D and 2D NMR along with HRESIMS. The anacardic acid derivatives were isolated from this species for the first time. All compounds exhibited significant inhibitory effect with IC₅₀ value of 0.75−3.60 μM against α-glucosidase.

Abstract Image

查看原文本刊更多论文

具有显著α-葡萄糖苷酶抑制活性的翅果茜草酸衍生物

我们不断努力从翅果茜草叶中寻找抗糖尿病成分，最终分离出一种新的无患子酸衍生物，2-[(Z)-壬烷-14-烯基]-6-羟基苯甲酸（1）以及四种已知的类似物（2-5）。新结构是通过大量光谱数据（包括一维和二维核磁共振以及 HRESIMS）阐明的。首次从该物种中分离出了心绞痛酸衍生物。所有化合物都对α-葡萄糖苷酶有明显的抑制作用，IC50 值为 0.75-3.60 μM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.